Ngassa Piotie et al. showed that 70% of the patients in their study were on an angiotensin converting enzyme (ACE)inhibitor.9 The RAASi appeared to be well tolerated, because only a minority (18.6%) of patients on RAASi developed hyperkalaemia, even among the CKD group. This evidence concerns the gene ACE and chronic kidney disease.